Regulatory Affairs

      VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults

      CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease,...

      LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer

      WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) has been accepted and granted Priority Review in the US for the adjuvant...

      Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related...

      TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that the U.S....

      Recent Articles

      Get a free copy of "Cracking the Generics Code"

      Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.